Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by OliX Pharmaceuticals, Inc.

News headline image
OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Commences Patient Dosing in Phase 1 Clinical Trial of OLX75016 for MASH
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide Combination Treatment
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA at Korea-US Digital·BioHealth Business Forum
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for Hair Loss
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Announces Positive Preclinical Data in NASH Non-human Primate Models
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-related Macular Degeneration
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals to Participate in BIO-Europe Spring®
From OliX Pharmaceuticals, Inc.
Via Business Wire
News headline image
OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress
From OliX Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.